CADL

4.9802.92%
FB

Francesca Barone

Chief Scientific Officer

Dr. Francesca Barone, M.D., Ph.D. serves as Chief Scientific Officer of Candel Therapeutics, Inc. since February 2022. Dr. Barone was Vice President and Head of Research at Candel Therapeutics, Inc. having joined the company in November 2020 until February 2022. Prior to that, she was its Head of Experimental Medicine. Dr. Barone served as Head of Experimental Medicine at Kintai Therapeutics, Inc, a Flagship Pioneering, Inc. company, from May 2019 through its merger into Senda Biosciences, Inc. Prior to that, she was a Rheumatology Consultant and Associate Professor (Reader) at University of Birmingham and at the Birmingham, Sandwell and West Birmingham NHS Foundation Trust in UK from 2010 to May 2019. In July 2016, Dr. Barone was awarded an ARUK Senior Fellowship to exploit the mechanisms enabling the persistence of tertiary lymphoid structures (TLS) in inflamed tissue and to investigate the pathogenicity of the stromal cells in TLS associated diseases. Dr. Barone obtained her M.D. at the University of Rome, Sapienza, and her Ph.D. in immunology at Kings College in London.

Positions